Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lipella Pharms Inc (LIPO)

Lipella Pharms Inc (LIPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 103
  • Shares Outstanding, K 4,621
  • Annual Sales, $ 540 K
  • Annual Income, $ -5,020 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.04
  • Price/Sales 5.87
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.43
  • Most Recent Earnings $-0.28 on 11/14/25
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0222 unch
on 04/02/26
0.1947 -88.60%
on 03/09/26
-0.1329 (-85.69%)
since 03/02/26
3-Month
0.0222 unch
on 04/02/26
0.3224 -93.11%
on 01/30/26
-0.1488 (-87.02%)
since 01/02/26
52-Week
0.0222 unch
on 04/02/26
3.1700 -99.30%
on 05/29/25
-2.5578 (-99.14%)
since 04/02/25

Most Recent Stories

More News
Lipella Pharmaceuticals Announces CMO Retirement

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lipella Pharmaceuticals,...

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus

All 27 patients completed treatment with no serious adverse events, underscoring a favorable safety profile Statistically significant improvements achieved across all efficacy endpoints at the 4-week...

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus

PITTSBURGH , Sept. 15, 2025 /PRNewswire/ -- Lipella Pharmaceuticals Inc.  (OTC: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company transforming care with innovative...

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

LIPO : 0.0222 (-54.51%)
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

LIPO : 0.0222 (-54.51%)
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

LIPO : 0.0222 (-54.51%)

Business Summary

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella Pharmaceuticals Inc. is based in PITTSBURGH.

See More

Key Turning Points

3rd Resistance Point 0.0609
2nd Resistance Point 0.0531
1st Resistance Point 0.0377
Last Price 0.0222
1st Support Level 0.0145
2nd Support Level 0.0067
3rd Support Level N/A

See More

52-Week High 3.1700
Fibonacci 61.8% 1.9675
Fibonacci 50% 1.5961
Fibonacci 38.2% 1.2247
Last Price 0.0222
52-Week Low 0.0222

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.